Aranesp

Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:

  • Myocardial infarction, or heart attack, as well as congestive heart failure
    Hypertension (high blood pressure), with increased risk of stroke
  • Venous thromboembolism
  • Thrombosis of vascular access
  • Tumor progression or recurrence

If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

Pre-Nuptial Agreements in New York: Doing Them Correctly!

There can be a variety of reasons for individuals entering into a pre-nuptial agreement. However unless a pre-nuptial agreement.... Read More

What to Do if CPS Contacts You

Written By: Attorney Elliot S. Schlissel To start with ask the investigator why they are investigating you. The investigators job.... Read More

Statement of Clients Rights and Responsibilities

The New York State Bar Association has promulgated documents called the Statements of Client’s Rights and Responsibilities. It gives clients.... Read More